Compass Group PLC Sponsored ADR (CMPGY)
OTC PINK OTC PINK Primary 
Compass Pathways to expedite launch timing of its experimental depression therapy
Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch timing of its experimental psilocybin-based depression therapy by 9 to 12 months.
CMPGY or CMG: Which Is the Better Value Stock Right Now?
Investors interested in Retail - Restaurants stocks are likely familiar with Compass Group PLC (CMPGY) and Chipotle Mexican Grill (CMG). But which of these two stocks offers value investors a better bang for their buck right now?
Compass Minerals International Is Still Deeply Undervalued
Compass Minerals International remains a "Buy" as shares are attractively valued and recent performance shows significant operational improvement. CMP's revenue and volumes, especially in salt and plant nutrition, are rising, while cost-cutting initiatives are improving cash flow and EBITDA. Despite higher net debt and leverage compared to peers, CMP trades at lower multiples, offering substantial upside potential versus industry averages.
Compass Stock Slides Over 15% In A Week, What's Next?
Compass Inc. stock (NYSE: COMP) has been experiencing significant pressure, having declined over 15% within the last week, while the S&P 500 only fell by 0.6%. The catalyst for this decline: Compass's agreement to acquire the competing brokerage Anywhere Real Estate in an all-stock transaction valued between $1.5 and $1.6 billion.
Anywhere Real Estate Stock Soars 51%. It's Being Bought by Compass.
The acquisition will create a real estate platform worth $10 billion in enterprise value.
Compass Group (CMPGY) Upgraded to Buy: Here's What You Should Know
Compass Group (CMPGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass: Buying The Dip - Gradual Stock Accumulation During Corrections
Compass is a market leader in real estate brokerage, showing strong growth and cost control despite a sluggish market. I expect the real estate market to improve as the Federal Reserve is likely to lower interest rates, which will benefit Compass. Compass has increased market share and agent count, demonstrating competitiveness and growth potential once the market recovers.
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC
Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC support dose expansion, with detailed phase 1 data expected in Q4 2025. Preclinical candidate CTX-10726 demonstrates potential superiority to competitors, with an IND submission targeted for Q4 2025.
Compass: Massive Leaps In Market Share
Compass' market share leaped to 6.09% in its most recent quarter, representing 96 bps of y/y expansion. The company achieved >20% growth in revenue, transactions, and transaction value, while the broader real estate industry contracted by -0.9%. The company is leveraging technology, M&A, and higher attach rates on post-sale services to drive both top-line and EBITDA growth.
Compass, Inc. (COMP) Q2 2025 Earnings Call Transcript
Compass, Inc. (NYSE:COMP ) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Soham Jairaj Bhonsle - Head of IR Robert L. Reffkin - Founder, Chairman & CEO Kalani Reelitz - CFO Conference Call Participants Bernard Jerome McTernan - Needham & Company, LLC Jason Stuart Helfstein - Oppenheimer & Co. Inc. Nick McAndrew - Zelman & Associates LLC Alec Reid Brondolo - Wells Fargo Securities, LLC Christopher Louis Kuntarich - UBS Investment Bank Michael Ng - Goldman Sachs Group, Inc. Elizabeth Ann Langan - Barclays Bank PLC Operator Ladies and gentlemen, thank you for joining us, and welcome to the Compass Second Quarter 2025 Earnings Call.
Compass, Inc. (COMP) Matches Q2 Earnings Estimates
Compass, Inc. (COMP) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago.
Compass, Inc. (COMP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Compass (COMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
